Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

New Drugs on the Horizon 2

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 5 of 5
Discovery of GDC-0077, a highly isoform selective inhibitor of PI3Kα that promotes selective loss of mutant-p110α
Steven T Staben
Genentech, Inc, Emerald Hills, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms
Stephen C. Alley
Seattle Genetics, Inc., Bothell, WA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
PRMT5 inhibitor: Novel clinical agent with therapeutic potential in heme and solid cancers
Olena Barbash
GlaxoSmithKline, Collegeville, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models
Dirk Brehmer
Janssen R&D, Beerse, Belgium
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by PDGFRA and KIT mutations
Erica K. Evans
Blueprint Medicines, Cambridge, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 5 of 5